Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
03 janv. 2023 16h01 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
08 nov. 2022 17h00 HE
|
Phathom Pharmaceuticals
Patient enrollment completed for Phase 3 non-erosive gastroesophageal reflux disease (NERD) daily dosing trial with topline data for primary endpoint expected in Q1 2023 Obtained commitment for up to...
Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences
03 nov. 2022 08h30 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
GerdLi: New Supplement for Heartburn Was Made by a Physician Who Sought Natural Heartburn Relief
01 nov. 2022 09h00 HE
|
www.gerdli.com
SEATTLE, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Physician-engineered GerdLi is the natural answer for people who live with acid reflux and heartburn. It's a premium-formulated antacid that maintains gut...
Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement
01 nov. 2022 08h00 HE
|
Phathom Pharmaceuticals
Up to $40 million committed, resulting in total financing of up to $300 million available to Phathom with total royalty payments capped at 2.0x invested capital Provides agreement for additional $15...
Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)
24 oct. 2022 08h00 HE
|
Phathom Pharmaceuticals
A total of 776 patients with symptomatic NERD have been enrolled and randomized in the multisite trial across the U.S.Topline data for the primary endpoint is expected in Q1 2023 with full trial...
Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
23 oct. 2022 12h01 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
18 oct. 2022 08h00 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
GerdLi is Changing How People Manage Acid Reflux - Naturally
26 sept. 2022 09h00 HE
|
GERDLI
SEATTLE, Sept. 26, 2022 (GLOBE NEWSWIRE) -- For millions of people, gastroesophageal reflux disease, or GERD, is a painful and uncomfortable condition that interrupts their life on a daily basis and...
Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors
26 sept. 2022 08h00 HE
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...